Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02759016
Title Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boehringer Ingelheim

chronic myeloid leukemia


BI 836826 + Ibrutinib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.